Every cloud has a silver lining: Proneurogenic effects of Aβ oligomers and HMGB-1 via activation of the RAGE-NF-κB axis

CNS and Neurological Disorders - Drug Targets

Volumn 16, Issue 10, 2017, Pages 1066-1079

  Bortolotto, Valeria ^a   Grilli, Mariagrazia ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Alzheimer s disease; A ; HMGB 1; Neurogenesis; Neuroinflammation; NF B; Oligomers; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID PRECURSOR PROTEIN; DISKS LARGE HOMOLOG 4; FLUOXETINE; GLIAL FIBRILLARY ACIDIC PROTEIN; HIGH MOBILITY GROUP B PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR; AMYLOID BETA PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; ENCEPHALITIS; HUMAN; LONG TERM POTENTIATION; MORRIS WATER MAZE TEST; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; PATHOPHYSIOLOGY; REVIEW; SPATIAL MEMORY; ANIMAL; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HMGB1 PROTEIN; HUMANS; NEUROGENESIS; NF-KAPPA B; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS; SIGNAL TRANSDUCTION;

EID: 85011629824     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527315666160803153459     Document Type: Review

References (169)

1. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-4.
2. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993; 143: 1699-712.
3. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell sur-face-binding proteins for advanced glycation end products. J Clin Invest 1993; 91: 2155-68.
4. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathway. J Biol Chem 1999; 274: 19919-24.
5. Dattilo BM, Fritz G, Leclerc E, Kooi CW, Heizmann CW, Chazin WJ. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 2007; 46: 6957-70.
6. Ostendorp T, Leclerc E, Galichet A, et al. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J 2007; 26: 3868-78.
7. Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 2003; 550: 107-13.
8. Fritz G. RAGE: a single receptor fits multiple ligands. Trends Biochem Sci 2001; 36: 625-32.
9. Hudson BI, Carte AM, Harja E, et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008; 22: 1572-80.
10. Kalea AZ, Reiniger N, Yang H, Arriero M, Schmidt AM, Hudson BI. Alternative splicing of the murine receptor for the advanced glycation end-products (RAGE) gene. FASEB J 2009; 23: 1766-74.
11. Ding Q, Keller JN. Evaluation of rage isoforms, ligands, and signaling in the brain. Biochim Biophys Acta 2005; 1746:18-27.
12. Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008; 22: 3716-27.
13. Hori O, Brett J, Slattery R, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 25752-61.
14. Yan SD, Stern D, Kan MD, Kuo YM, Lampert HC, Roher AE. Rage-Abeta interactions in the pathophysiology of Alzheimer’s disease. Restor Neurol Neurosci 1998; 12: 167-73.
15. Chavakis T, Bierhaus A, Al-Fakhri N, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198: 1507-15.
16. Grilli M, Memo M. Nuclear Factor-κB/Rel proteins: A point of convergence of signalling pathways relevant in neuronal function and dysfunction. Biochem Pharmacol 1999; 57: 1-7.
17. Basta G, Lazzerini G, Massaro M, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: A mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816-22.
18. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272: 17810-4.
19. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63: 582-92.
20. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 2014; 18: 1-14.
21. Thornalley PJ. Glycation in diabetics neuropathy: Characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 2002; 50: 37-57.
22. Sasaki N, Fukatsu R, Tsuzuki K, et al. Advanced glycation end products in Alzheimer’s disease and other neurodegenerative diseases. Am J Pathol 1998; 153:1149-55.
23. Shuvaev VV, Laffont I, Serot JM, Fujii J, Taniguchi N, Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer’s disease. Neurobiol Aging 2001; 22: 397-402.
24. Luth HJ, Ogunlade V, Kyhla B, et al. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer’s disease brains. Cereb Cortex 2005; 15: 211-20.
25. Muller S, Bianchi ME, Knapp S. Thermodynamics of HMGB-1 interaction with duplex DNA. Biochemistry 2001; 40: 10254-61.
26. Anderson U, Tracey KJ. HMGB1 is a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum Dis Clin North Am 2004; 30: 627-37.
27. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5.
28. Yang H, Wang H, Czura CJ, Tracey KJ. The cytokine activity HMGB1. Leukoc Biol 2005; 78: 1-8.
29. Takata K, Kitamura Y, Kakimura J, et al. Role of high mobility group box protein-1 (HMGB-1) in amyloid-beta homeostasis. Biochem Biophys Res Commun 2003; 301: 699-701.
30. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274: 19919-24.
31. Passalacqua M, Patrone M, Picotti GB, et al. Stimulated astrocytes release high-mobility group 1 protein, an inducer of LAN-5 neuroblastoma cell differentiation. Neuroscience 1998; 82: 1021-8.
32. Palumbo R, Sampaolesi M, De Marchis F, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004; 164: 441-9.
33. Donato R. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biol Cell Biol 2001; 33: 637-68.
34. Heizmann CW, Fritz G, Schäfer BW. S100 proteins: Structure, functions and pathology. Front Biosci 2002; 7: d1356-68.
35. Van Eldik LJ, Zimmer BD. Secretion of S-100 from rat C6 glioma cells. Brain Res 1987; 436: 367-70.
36. Ponath G, Schettler C, Kaestner F, et al. Autocrine S100B effects on astrocytes are mediated via RAGE. J Neuroimmunol 2007; 184: 214-22.
37. Adami C, Sorci G, Blasi E, Agneletti AL, Bistoni F, Donato R. S100B expression in and effects on microglia. Glia 2001; 33: 131-42.
38. Liu L, Li Y, Van Eldik LJ, Griffin WS, Barger SW. S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors. J Neurochem 2005; 92: 546-53.
39. Adami C, Bianchi R, Pula G, Donato R. S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain. Biochim Biophys Acta 2004; 1742: 169-77.
40. Bianchi R, Adami C, Giambanco I, Donato R. S100B binding to RAGE in microglia stimulates COX-2 expression. J Leukoc Biol 2007; 8: 108-18.
41. Gruden MA, Daridova TB, Malisauskas M, et al. Differential neu-roimmune markers to the onset of Alzheimer’s disease neurodegeneration and dementia: Autoantibodies to Abeta((25-35)) oligomers, S100b and neurotransmitters. J Neuroimmunol 2007; 186: 181-92.
42. Arancio O, Zhang HP, Chen X, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 2004; 23: 4096-105.
43. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9: 907-13.
44. Chou DK, Zhang J, Smith FI, McCaffery P, Jungalwala FB. Developmental expression of receptor for advanced glycation end products (RAGE), amphoterin and sulfoglucuronyl (HNK-1) carbohydrate in mouse cerebellum and their role in neurite outgrowth and cell migration. J Neurochem 2004; 90: 1389-401.
45. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD. RAGE: A potential target for Abeta mediated cellular perturbation in Alzheimer’s disease. Curr Mol Med 2007; 7: 735-42.
46. Rauvala H, Pihlaskari R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowt in central neurons. J Biol Chem 1987; 262: 16625-35.
47. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000; 275: 40096-105.
48. Sajithal G, Huttunen H, Rauvala H, Munch G. Receptor for advanced glycation end products plays a more important role in cellular survival than in neurite outgrowth during retinoic acid-induced differentiation of neuroblastoma cells. J Biol Chem 2002; 277: 6888-97.
49. Rong LL, Yan SF, Wendt T, et al. RAGE modulates pheripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB 2004; 18: 1818-25.
50. Rong LL, Trojaborg W, Qu W, et al. Antagonism of RAGE suppresses pheripheral nerve regeneration. FASEB 2004; 18: 1812-17.
51. Vincent AM, Perrone L, Sullivan KA, et al. Receptor for advanced glycation end products activation injuries primary sensory neurons via oxidative stress. Endocrinology 2007; 148: 548-58.
52. Selinfreud RH, Barger SW, Pledger WJ, Van Eldik LJ. Neurotrophic protein S100 beta stimulates glial cell proliferation. Proc Natl Acad Sci 1991; 88: 3554-58.
53. Hirota H, Kiyama H, Kishimoto T, Taga T. Accelerated nerve re generation in mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. J Exp Med 1996; 183: 2627-34.
54. Sarkar D, Fisher PB. Molecular mechanisms of aging-associated inflammation. Cancer Lett 2004; 236: 13-23.
55. Lam AG, Koppal T, Akama KT, et al. Mechanism of glial activation by S100B: Involvement of the transcription factor NF-kappaB. Neurobiol Aging 2001; 22: 765-72.
56. Bianchi R, Giambanco I, Donato R. S100B/RAGE-dependent activation of microglia via NF-kappaB and Ap-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol Aging 2010; 31: 665-77.
57. Xie J, Méndez JD, Méndez-Valenzuela V, Aguilar-Hernández MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal 2013; 25: 2185-97.
58. Grilli M, Chiu JJ-S, Lenardo MJ. NF-κB and Rel: Partecipants in a multiform transcriptional regulatory system. Int Rew Cytol 1993; 143: 1-62.
59. Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H, Baeuerle PA. Constitutive NF-κB activity in neurons. Mol Cell Biol 1994; 14: 3981-92.
60. Wellman H, Kaltschmidt B, Kaltschmidt C. Retrograde transport of transcription factor NF-kappa B in living neurons. J Biol Chem 2001; 276: 11821-29.
61. Grilli M, Pizzi M, Memo M, Spano PF. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science 1996; 274: 1383-5.
62. Grilli M, Memo M. Transcriptional pharmacology of neurodegenerative disorders: Novel venue towards neuroprotection against excitotoxicity? Mol Psychiatry 1997; 2: 192-4.
63. Grilli M, Memo M. Possible role of NF-κB and p53 in the glutamate-induced pro-apoptotic neuronal pathway. Cell Death Differ 1999; 6: 22-7.
64. Grilli M, Memo M. Nuclear Factor-κB/Rel proteins: A point of convergence of signalling pathways relevant in neuronal function and dysfunction. Biochem Pharmacol 1999; 57: 1-7.
65. Uberti D, Grilli M, Memo M. Contribution of NF-κB and p53 in the glutamate-induced apoptosis. Int J Dev Neurosci 2000; 18: 447-54.
66. Nafez S, Oikawa K, Odero GL, et al. Early growth response 2 (Egr-2) expression is triggered by NF-kB activation. Mol Cell Neurosci 2015; 64: 95-103.
67. Albensi BC, Mattson MP. Evidence for the involvement of TNF and NF-κB in hippocampal synaptic plasticity. Synapse 2000; 35: 151-9.
68. Kaltschmidt B, Ndiaye D, Korte M, et al. NF-κB regulates spatial memory formation and synaptic plasticity through protein kinase A/CREB signaling. Mol Cell Biol 2006; 26: 2936-46.
69. Boccia M, Freudenthal R, Blake M, et al. Activation of hippocampal nuclear factor κB by retrieval is required for memory reconsoli-dation. J Neurosci 2007; 27: 13436-45.
70. Federman N, de la Fuente V, Zalcman G, et al. Nuclear factor κB-dependent histone acetylationis specifically involved in persistent form memory. J Neurosci 2013; 33: 7603-14.
71. Bonini SA, Ferrari-Toninelli G, Uberti D, et al. Nuclear factor κB-dependent neurite remodelling is mediated by notch pathway. J Neurosci 2011; 31: 11697-705.
72. Gutierrez H, Davies AM. Regulation of neural process growth, elaboration and structural plasticity by NF-κB. Trends Neurosci 2011; 34: 316-25.
73. Snow WM, Stoesz BM, Kelly DM, Albensi BC. Roles of NF-κB gene targets of NF-κB in synaptic plasticity, memory and navigation. Mol Neurobiol 2014; 49: 757-70.
74. Bortolotto V, Cuccurazzu B, Canonico PL, Grilli M. NF-κB mediated regulation of adult hippocampal neurogenesis: Relevance in mood disorders and in antidepressant activity. Biomed Res Int 2014; 214: 612798.
75. Kaltschmidt B, Kaltschmidt C. NF-kappaB in the nervous system. Cold Spring Harb Perspest Biol 2009: 1:a001271.
76. Meffert MK, Chang JM, Wiltgen BJ, Fanselow MS, Baltimore D. NF-kappaB functions in synaptic signaling and behavior. Nat Neurosci 2003; 6: 1072-78.
77. Levenson JM, Choi S, Lee SY, et al. A bioinformatics analysis of memory consolidation reveals involvement of the transcription factor c-rel. J Neurosci 2004; 24: 3933-43.
78. Ahn HJ, Hernandez CM, Levenson JM, Lubinm FD, Liou HC, Sweatt JD. c-Rel, an NF-kappaB family transcription factor, is required for hippocampal long-term synaptic plasticity and memory formation. Lean Mem 2008; 15: 539-49.
79. Kassed CA, Willing AE, Garbuzova-Davis S, Sanberg PR, Penny-packer KR. Lack of NF-kappaB p50 exacerbates degeneration of hippocampal neurons after chemical exposure and impairs learning. Exp Neurol 2002; 176: 277-88.
80. Denis-Donini S, Dellarole A, Crociara P, et al. Impaired adult neurogenesis associated with short term memory defects in NF-κB p50-deficent mice. J Neurosci 2008; 28: 3911-19.
81. Oikawa K, Odero GL, Platt E, et al. NF-κB p50 subunit knockout impairs late LTP and alters long term memory in the mouse hippocampus. BMC Neurosci 2012; 13: 45.
82. Bracchi-Ricard V, Brambilla R, Levenson J, et al. Astroglial nuclear factor-kappaB regulates learning and memory and synaptic plasticity in female mice. J Neurochem 2008; 104: 611-23.
83. Grilli M, Ribola M, Alberici A, Valerio A, Memo M, Spano PF. Identification and characterization of a κB/Rel binding site in the regulatory region of the Amyloid Precursor Protein gene. J Biol Chem 1995; 270: 26774-77.
84. Grilli M, Goffi F, Memo M, Spano PF. Interleukin-1β and glutamate activate the NF-κB/Rel binding site from the regulatory region of the Amyloid Precursor Protein gene in primary neuronal cultures. J Biol Chem 1996; 271: 15002-7.
85. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer’s disease. Proc Nat Acad Sci USA 1997; 94: 2642-47.
86. Terai K, Matsuo A, McGeer PL. Enhancement of immunoreactivity for NF-kappaB in the hippocampal formation and cerebral cortex of Alzheimer’s disease. Brain Res 1996; 735: 159-68.
87. Kaltschmidt B, Uherek M, Wellman H, Volk B, Kaltschmidt C. Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis. Proc Nat Acad Sci USA 1999; 96: 9409-14.
88. Boissère F, Hunot S, Faucheux B, et al. Nuclear translocation of NF-kappaB in cholinergic neurons of patients with Alzheimer’s disease. Neuroreport 1997; 8: 2849-52.
89. Valerio A, Boroni F, Benarese M, et al. NF-kappaB pathway: A target for preventing beta-amyloid (Abeta)- induced neuronal damage and Abeta42 production. Eur J Neurosci 2006; 23: 1711-20.
90. Barger SW, Mattson MP. Participation of gene expression in the protection against amyloid beta-peptide toxicity by the beta amyloid precursor protein. Ann N Y Acad Sci 1996; 777: 303-9.
91. Barger SW, Mattson MP. Induction of neuroprotective kappa B-dependent transcription by secreted forms of the Alzheimer’s beta-amyloid precursor. Brain Res Mol Brain Res 1996; 40: 116-26.
92. Walker DG, Lue LF, Beach TG. Gene expression profiling of amyloid beta peptide-stimulated human post mortem brain microglia. Neurobiol Aging 2001; 22: 957-66.
93. Chen J, Zhou Y, Mueller-Steiner S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005; 280: 40364-74.
94. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 1996; 382: 685-91.
95. Lue LF, Walker DG, Brachova L, et al. Involvement of microglial receptor for advanced glycation end products (RAGE) in Alzheimer’s disease: Identification of a cellular activation mechanism. Exp Neurol 2001; 171: 29-45.
96. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-55.
97. Takata K, Kitamura Y, Kakimura J, et al. Role of high mobility group protein-1 (HMG1) in amyloid-beta homeostasis. Biochem Biophys Res Commun 2003; 301: 699-703.
98. Shepherd CE, Goyette J, Utter V, et al. Inflammatory S100A9 and S100A12 proteins in Alzheimer’s disease. Neurobiol Aging 2006; 27: 1554-63.
99. Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease. Brain Res 2001; 888: 256-62.
100. Nozaki I, Watanabe T, Kawaguchi M, et al. Reduced expression of endogenous secretory receptor for advanced glycation end products in hippocampal neurons of Alzheimer’s disease brains. Arch Histol Cytol 2007; 70: 279-90.
101. Li K, Dai D, Zhao B, et al. Association between the RAGE G82S polymorphism and Alzheimer’s disease. J Neural Transm 2009; 117: 97-104.
102. Geroldi D, Falcone C, Minoretti P, Emanuele E, Arra M, D’Angelo A. High levels of soluble receptor for advanced glycation end products may be a marker for extreme longevity in humans. J Am Geriatr Soc 2006; 54: 1149-50.
103. Takeuchi M, Sato T, Takino J, et al. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer’s disease. Med Hypotheses 2007; 69: 1358-66.
104. Sturchler E, Galichet A, Weiberl M, Lecler E, Heizmann CW. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J Neurosci 2008; 28: 5149-58.
105. Herold K, Moser B, Chen Y, et al. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: Inflammatory signals gone awry in the primal response to stress. J Leukoc Biol 2007; 82: 204-12.
106. Fang F, Lue LF, Yan S, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease. FASEB J 2010; 24: 1043-55.
107. Origlia N, Bonadonna C, Rosellini A, et al. Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex. J Neurosci 2010; 30: 11414-25.
108. Du Yan S, Zhu H, Fu J, et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer's disease. Proc Natl Acad Sci USA 1997; 94: 5296-301.
109. Takuma K, Fang F, Zhang W, et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci USA 2009; 106: 20021-6.
110. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997; 272: 16498-506.
111. Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM. Receptor for AGE (RAGE): Weaving tangled webs within the inflammatory response. Curr Mol Med 2007; 7: 743-51.
112. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 1996; 382: 685-91.
113. Cho HJ, Son SM, Jin SM, et al. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J 2009; 23: 2639-49.
114. Origlia N, Righi M, Capsoni S, et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci 2008; 28: 3521-30.
115. Mackic JB, Stins M, McComb JG, et al. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain mi-crovascular endothelial cell monolayer. J Clin Invest 1998; 102: 734-43.
116. Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2007; 4: 191-7.
117. Leclerc E, Sturchler E, Vetter S. The S100/RAGE axis in Alzheimer’s disease. Cardiovasc Psychiatry Neurol 2010; 2010: 539581.
118. Esposito G, Scuderi C, Lu J, et al. S100B induces tau protein hy-perphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J Cell Mol Med 2008; 12: 914-27.
119. Monnier VM, Cerami A. Nonenzymatic browning in vivo: Possible process for aging of long-lived proteins. Sciences 1981; 211: 491-3.
120. Gasser A, Forbes JM. Advanced glycation: Implications in tissue damage and disease. Protein Pept Lett 2008; 15: 385-91.
121. Kimura T, Takamatsu J, Araki N, et al. Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease? Neuroreport 1995; 6: 866-8.
122. Li J, Liu D, Sun L, Lu Y, Zhang Z. Advanced glycation end products and neurodegenerative diseases: Mechanisms and perspective. J Neurol Sci 2012; 317: 1-5.
123. Loske C, Gendermann A, Schepi W, et al. Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur J Biochem 2000; 267: 4171-8.
124. Srikanth V, Maczurek A, Phan T, et al. Advanced glycation end-products and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2011; 32: 763-77.
125. Kokkola R, Andersson A, Mullins G, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005; 61: 1-9.
126. Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 7370-7.
127. Takata K, Kitamura Y, Tsuchiya D, Kawasaki T, Taniguchi T, Shimohama S. High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. J Neurosci Res 2004; 78: 880-91.
128. Takata K, Takada T, Ito A, et al. Microglial amyloid-β1-40 phago-cytosis dysfunction is caused by high-mobility group box protein-1: Implications for the pathological progression of alzheimer's disease. Int J Alzheimers Dis 2012; 201: 685739.
129. Mazarati A, Maroso M, Iori V, Carli M. High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and the receptor for advanced glycation end products. Exp Neurol 2011; 232: 143-8.
130. Lue LF, Yan SD, Stern DM, Walker DG. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2005; 4: 249-66.
131. Maczuker A, Shanmugan K, Müchen G. Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease. Ann N Y Acad Sci 2008; 1126: 147-51.
132. Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012; 122: 1377-92.
133. Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 2011; 25: 206-12.
134. Galasko D, Bell J, Mancuso JY, et al. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology 2014; 82: 1536-42.
135. Vodopivec I, Galichet A, Knobloch M, Bierhaus A, Heizmann CW, Nitsch RM. RAGE does not affect amyloid pathology in transgenic ArcAbeta mice. Neurodegener Dis 2009; 6: 270-80.
136. Denis-Donini S, Caprini A, Frassoni C, Grilli M. Members of the NF-κB family expressed in zone of active neurogenesis in the postnatal and adult mouse brain. Brain Res Dev Brain Res 2005; 154: 81-9.
137. Grilli M, Meneghini V. In: Transcription Factors CREB and NF-κB: Involvement in Synaptic Plasticity and Memory Formation, Ed. Bentham Science Publishers Ltd. 2012; pp. 79-96.
138. Valente MM, Allen M, Bortolotto V, et al. The MMP1/PAR-1 axis enhances proliferation and neuronal differentiation of adult hippocampal Neural progenitor Cells. Neural Plast 2015; 2015: 646595.
139. Widera D, Mikenberg I, Elvers M, Kaltschmid C, Kaltschmidt B. Tumor necrosis factor α triggers proliferation of adult neural stem cells via IKK/NF-κB signaling. BMC Neurosci 2006; 7: 64.
140. Bernardino L, Agasse F, Silva B, Ferreira R, Grade S, Malva OJ. Tumor necrosis factor-alpha modulates survival, proliferation, and neuronal differentiation in neonatal subventricular zone cell cultures. Stem Cells 2008; 26: 2361-71.
141. Shingo T, Todd Sorokan S, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neural progenitors by mammalian forebrain neural stem cells. J Neurosci 2001; 21: 9733-43.
142. Wada T, Haigh JJ, Ema M, et al. Vascular endothelial growth factor directly inhibits primitive neural stem cell survival but promotes definitive neural stem cell survival. J Neurosci 2006; 26: 6803-12.
143. Brazel CY, Nuñez JL, Yang Z, Levison SW. Glutamate enhances survival and proliferation of neural progenitors derived from the subventricular zone. Neuroscience 2005; 131: 55-65.
144. Koo JW, Duman RS. IL-1beta is an essential mediator of the anti-neurogenic and anhedonic effects of stress. Proc Natl Acad USA 2008; 105: 751-56.
145. Rolls A, Shechter R, London A, et al. Toll-like receptors modulates adult hippocampal neurogenesis. Nat Cell Biol 2007; 9: 1081-88.
146. Widera D, Holtkamp W, Entschladen F, et al. MCP-1 induces migration of adult neural stem cells. Eur J Cell Biol 2004; 83: 381-7.
147. Zhang Y, Liu J, Yao S, et al. Nuclear factor kappa B signaling initiates early differentiation of neural stem cells. Stem Cells 2012; 30: 510-24.
148. Imielski Y, Schwamborn C, P Lüningschör, et al. Regrowing the adult brain: NF-κB controls functional circuit formation and tissue homeostasis in the dentate gyrus. PLoS One 2012; 7: e30838.
149. Valente MM, Bortolotto V, Cuccurazzu B, et al. α2δ ligands act as positive modulators of adult hippocampal neurogenesis and prevent depression-like behavior induced by chronic restraint stress. Mol Pharmacol 2012; 82: 271-280.
150. Cuccurazzu B, Bortolotto V, Valente MM, et al. Upregulation of mGlu2 receptors via NF-κB p65 acetylation is involved in the Proneurogenic and antidepressant effects of acetyl-l-carnitine. Neu-ropsychopharmacology 2013; 38: 2220-30.
151. Mu Y, Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer’s disease. Mol Neurodegener 2011; 22: 85.
152. Rodriguez, Verkharatsky A. Neurogenesis in Alzheimer’s disease. J Anat 2011; 219: 78-89.
153. Meneghini V, Francese MT, Carraro L, Grilli M. A novel role for the receptor for Advanced Glycation End-products in neural progenitor cells derived from adult SubVentricula Zone. Mol Cell Neurosci 2010; 45: 139-50.
154. Manev H, Uz T, Manev R. Glia as a putative target for antidepressant treatment. J Affect Disord 2003; 75: 59-64.
155. Meneghini V, Bortolotto V, Francese MT, et al. High-mobility group box-1 protein and β-amyloid oligomers promote neuronal differentiation of adult hippocampal neural progenitors via receptor for advanced glycation end products/nuclear factor-κB axis: Relevance for Alzheimer’s disease. J Neurosci 2013; 33: 6047-59.
156. Chisthi MA, Yang DS, Janus C, et al. Early-onset amyloid beta deposition and cognitive deficits in transgenic mice overexpressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001; 276: 21562-70.
157. Hyde LA, Kazdoba TM, Grilli M, et al. Age-progressing cognitive impairments and neuropathology in transgenic CRND8 mice. Behav Brain Res 2005; 160: 344-55.
158. Lόpez-Toledano MA, Shelanski ML. Neurogenic effect of beta-amyloid peptide in the development of neural stem cells. J Neurosci 2004; 24: 5439-44.
159. Heo C, Chang KA, Choi HS, et al. Effects of monoaminergic, oligomeric, and fibrillar Abeta42 peptides on the proliferation and differentiation of adult stem cells for subventricular zone. J Neurochem 2007; 102: 493-500.
160. Puzzo D, Privitera L, Leznik E, et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 2008; 28: 14537-45.
161. Lei C, Lin S, Zhang C, et al. Effects of high-mobility group box1 on cerebral angiogenesis and neurogenesis after intracerebral hemorrhage. Neuroscience 2013; 229: 12-9.
162. Kleindienst A, McGinn MJ, Harvey HB, Colello RJ, Hamm RJ, Bullock MR. Enhanced hippocampal neurogenesis by intraven-tricular S100B infusion is associated with improved cognitive re- covery after traumatic brain injury. J Neurotrauma 2005; 22: 645-55.
163. Yan SS, Chen D, Yan S, Guo L, Du H, Chen JX. RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer’s disease. Front Biosci (Schol Ed) 2012; 4: 240-50.
164. Srikanth V, Maczurek A, Phan T, et al. Advanced glycation end-products and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging 2011; 32: 763-77.
165. Perrone L, Sbai O, Nawroth PP, Bierhaus A. The complexity of sporadic Alzheimer’s disease pathogenesis: The role of RAGE as therapeutic target to promote neuroprotection by inhibiting neurovascular dysfunction. Int J Alzheimers Dis 2012; 2012: 734956.
166. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 2004; 44: 181-93.
167. Glabe CC. Amyloid accumulation and pathogenesis of Alzheimer’s disease: Significance of monomeric, oligomeric and fibrillar Abeta. Subcell Biochem 2005; 38: 167-77.
168. Li B, Yamamori H, Tatebayashi Y, et al. Failure of neuronal maturation in Alzheimer disease dentate gyrus. J Neuropathol Exp Neurol 2008; 67: 78-84.
169. Schaeffer EL, Novaes BA, de Silva ER, Skaf HD, Mendes-Neto AG. Strategies to promote differentiation of newborn neurons into mature functional cells in Alzheimer brain. Prog Neuropsy-chopharmacol Biol Psychiatry 2009; 33: 1087-102.